-
公开(公告)号：US20200033369A1
公开(公告)日：2020-01-30
申请号：US16566387
申请日：2019-09-10
发明人： Elena Grimberg , Roberto Meidler , Yonit Tiberman , Nadav Orr , Nadav Ashkenazy
摘要： The present invention is directed to devices having a substance receiving portion; a membrane; and at least one blocking member configured for taking one position and another position to allow fluid communication when a vacuum force is applied to the bottom of the substance receiving portion for the purpose of an in-situ preparation of a sample to detect the presence of, and/or quantify, clottable fibrinogen. The present invention is also directed to corresponding methods, processes and systems.
-
公开(公告)号：US10539559B2
公开(公告)日：2020-01-21
申请号：US14420122
申请日：2013-08-06
发明人： Kentaro Yamaguchi , Katsumi Aoyagi , Azusa Terao
IPC分类号： G01N33/543 , G01N33/86 , C07K14/745 , G01N33/574
摘要： Disclosed are a PIVKA-II measurement method that achieves better serum-plasma correlation than conventional methods, and a reagent and a kit therefor. The PIVKA-II measurement method according to the present invention comprises measuring PIVKA-II in a sample by an immunoassay using a mixture of an anti-F1 antibody that specifically binds to prothrombin fragment F1 or an antigen-binding fragment thereof and an anti-F2 antibody that specifically binds to prothrombin fragment F2 or an antigen-binding fragment thereof; and an anti-PIVKA-II antibody that specifically binds to PIVKA-II or an antigen-binding fragment thereof.
-
公开(公告)号：US10534006B2
公开(公告)日：2020-01-14
申请号：US15909677
申请日：2018-03-01
发明人： Sasha Bakhru , Bryan Laulicht , Stefan Zappe , Solomon Steiner
摘要： A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.
-
公开(公告)号：US20200011884A1
公开(公告)日：2020-01-09
申请号：US16572567
申请日：2019-09-16
申请人： C A Casyso AG
摘要： Embodiments of a blood coagulation testing system can operate as an automated thromboelastometry system that is particularly useful, for example, at a point-of-care site. In some embodiments, the blood coagulation testing system includes a single-use cartridge component configured to measure and mix reagents with blood received from a blood sample reservoir. A mixing chamber in the single-use cartridge includes different reagent beads that, when exposed to a pre-determined volume of blood, dissolve and mix specific reagents with the blood. The assembled blood cartridge further includes configurations that are designed to prevent blood from prematurely mixing with reagent beads in the mixing chamber and to guide blood flow in the mixing chamber to dissolve reagent beads in a desired order. Thus, the mixture obtained from the mixing chamber can be readily utilized to generate results for the blood coagulation testing system.
-
公开(公告)号：US20190383815A1
公开(公告)日：2019-12-19
申请号：US16480342
申请日：2018-01-25
发明人： Esther RABIZADEH , Izchak CHERNY , Aida INBAL
IPC分类号： G01N33/574 , G01N33/86
摘要： A method for diagnosing a malignant proliferative disease or disorder in a subject, and/or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.
-
公开(公告)号：US20190353674A1
公开(公告)日：2019-11-21
申请号：US16528871
申请日：2019-08-01
IPC分类号： G01N33/86
摘要： Provided is a method of accurately and easily determining a cause of the prolongation of blood coagulation time.The method of determining a cause of the prolongation of blood coagulation time in test plasma includes (1) measuring the blood coagulation time of samples including (a) the test plasma only, (b) normal plasma only, and (c) the test plasma and the normal plasma mixed at least at a mixing ratio, (2) drawing a polygonal line graph by plotting the measurement results of the samples (a), (b) and (c), with the vertical axis representing the blood coagulation time or the prolongation ratio of blood coagulation time and the horizontal axis representing the mixing ratio or mixing proportion of the test plasma or the normal plasma, and thereby determining the area A under the polygonal line and the area B under a line segment that connects the plotted measurement results of the samples (a) and (b), (3) calculating the ratio of the area (A−B) obtained by subtracting the area B from the area A, with respect to the area B, ((A−B)/(B)): area ratio X), (4) performing the steps of (1) and (2) for a coagulation factor inhibitor-positive plasma, and thereby determining in advance a standard area ratio Y, and (5) comparing the area ratio X and the standard area ratio Y, and determining the test plasma as a coagulation factor inhibitor type in the case where Y≤X, or as a coagulation factor deficient type in the case where Y>X.
-
公开(公告)号：US10466257B2
公开(公告)日：2019-11-05
申请号：US14095657
申请日：2013-12-03
申请人： Sony Corporation
摘要： There is provided an electrical measuring container of a biological sample in a liquid phase, including at least a biological sample holding section configured to accommodate a biological sample in a liquid phase and made of a resin, and an electrical conductive section fixed to the biological sample holding section. In a state in which a portion of the electrical conductive section is buried in the biological sample holding section, the biological sample holding section and the electrical conductive section are integrally formed with each other.
-
公开(公告)号：US20190323059A1
公开(公告)日：2019-10-24
申请号：US16375413
申请日：2019-04-04
发明人： Deanna Porter , Kent Grove
摘要： An apparatus for in vitro testing of medical device thrombogenicity includes an enclosure; a heating element thermally coupled to the enclosure; and a temperature feedback circuit operably coupled to the heating element and configured to control the heating element to maintain an interior of the enclosure within a preset temperature range. Positive, negative, and intermediate control rods are provided as standards against which to compare a medical device test article. Multiple blood test loops can be established through the enclosure using a common blood supply. The medical device test article can be placed in one of the loops, while the remaining loops can contain controls. Blood can be circulated through the test loops at a flow rate similar to that encountered in vivo, and thrombus formation can be assessed thereafter.
-
公开(公告)号：US20190272637A1
公开(公告)日：2019-09-05
申请号：US16419067
申请日：2019-05-22
IPC分类号： G06T7/00 , G06T7/62 , G01N15/00 , G06T7/13 , G06T7/70 , G06T7/90 , G01N21/51 , G06T5/00 , G06K9/62 , G06K9/52 , G01N33/86 , G06K9/46
摘要： The present application describes a new device and method of use thereof, which allows identifying certain antigens and antibodies present in the blood. The device of the present invention is a closed device consisting of two parts, wherein the upper part has a chamber surrounded by LEDs illuminating the analysis plate, which is supported by the rotating platform. In turn, the rotating platform is connected to a motor that will promote the rotation thereof for mixing reagents with blood. After a period of time, the camera will capture and send the resulting image to a computer program that will analyze the sample, using image processing techniques.
-
公开(公告)号：US20190210856A1
公开(公告)日：2019-07-11
申请号：US16097556
申请日：2017-05-02
发明人： Feng JIANG , Jian XIAO , Gong LIU , Aiqin CHEN , Bangzhong YU
摘要： A cap removal device and a thrombelastography device having same are disclosed. The cap removal device comprises a drive part (1), a connection shaft (2), and a cap removal member (3). The connection shaft (2) can move upward when driven by the drive part (1). The cap removal member (3) has an end (31) and the other end (32); the end (31) is pivotally connected to the connection shaft (2), so that when the connection shaft (2) moves upward when driven by the drive part (1), the cap removal member (3) rotates, due to the upward movement, around a pivot point (4) located between the end (31) and the other end (32) of the cap removal member (3), so that the other end (32) of the cap removal member (3) moves downward to contact a cap (5) to be removed, thereby removing the cap (5). The thrombelastography device has the cap removal device, and thus can achieve the automatic removal of the cap (5) and the automated control on the drive part (1), thereby improving the cap removal efficiency and the test efficiency, and saving time of manually removing the cap.
-
-
-
-
-
-
-
-
-
搜索结果
1751 条记录 (耗时 0.042 秒)